The US Food and Drug Administration (FDA) has added new warnings to the Pfizer and Moderna COVID-19 vaccines about a rare heart condition that mostly affects young men.

Dr. Jeffrey Kopin, Chief Medical Officer for Northwestern Medicine Lake Forest Hospital, joins John Williams to talk about ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

A new warning for the latest round of COVID-19 vaccines from Pfizer and Moderna has been issued by the U.S. Food and Drug ...

The Food and Drug Administration has updated its warning labels for the Pfizer and Moderna COVID-19 vaccines, expanding information about a rare but potential heart-related side effect. The updated ...

Specifically, the new warning lists the risk of myocarditis as 8 cases per 1 million people who got the 2023-2024 COVID shots ...

Moderna’s stock has also shown heightened sensitivity during market downturns. In the 2022 inflation shock, the stock plummeted 53.4%, compared to a 25.4% decline in the S&P 500.

Its market cap is down to $15 billion. Compared to revenue of $5 billion and $9 billion in cash on the balance sheet, Moderna is an interesting opportunity for a turnaround bet at current prices.

Moderna's success with COVID-19 vaccine approval under Operation Warp Speed led to a temporary revenue surge, but future sales may be limited due to politicization of vaccines and competition.

UPDATE (9/6/23): This story has been updated with information from a Moderna clinical trial suggesting its updated vaccine is effective against EG.5. A new strain of COVID-19 called EG.5 has been ...

UPDATE (9/6/23): This story has been updated with information from a Moderna clinical trial suggesting its updated vaccine is effective against EG.5. A new strain of COVID-19 called EG.5 has been ...